Back to results
US 8,278,453 B2Granted
Quinolizidinone M1 receptor positive allosteric modulators
AssigneeMerck Sharp & Dohme Corp.
InventorsScott D. Kuduk, Christina Ng Di Marco
Life of this patent
Estimating the term…
Abstract
The present invention is directed to quinolizidinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.
Claims10
A compound of formula (I)
- or a pharmaceutically acceptable salt thereof, wherein
- X is N or CH, and
- Y is N or CH, provided that both X and Y are not N;
- Q is selected from the group consisting of
- (1) —CH2—,
- R1 is selected from the group consisting of
- (1) hydrogen,
- (2) —C1-6 alkyl, or
- (3) —CH2-aryl,
- wherein said R1 alkyl or aryl moiety is optionally substituted with one or more
- (a) halogen,
- (b) cyano, and
- (c) —O—C1-6 alkyl, wherein said alkyl is optionally substituted with one or more halogen;
- R2 is selected from the group consisting of
- (2) heteroaryl, wherein said heteroaryl is a cyclic or polycyclic aromatic ring system having from four to twelve ring atoms, said ring atoms selected from C, CH, C═O, N or O,
- (3) —C6-10 aryl,
- wherein the aryl or heteroaryl ring is optionally substituted with one or more
- (a) —C1-6 alkyl,
- (b) —OC1-6 alkyl,
- (c) —C6-10 aryl, or
- (d) halogen;
- and provided that at least one of X, Y, or R2 contains a nitrogen atom.
19 more elements
Dependencies are inferred from the claim text.